Viewing Study NCT00362102


Ignite Creation Date: 2025-12-25 @ 3:56 AM
Ignite Modification Date: 2026-01-07 @ 1:47 PM
Study NCT ID: NCT00362102
Status: COMPLETED
Last Update Posted: 2016-11-22
First Post: 2006-08-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module